top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Laboratory testing in the era of precision medicine : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session, on examining laboratory testing in the era of precision medicine, September 20, 2016
Laboratory testing in the era of precision medicine : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session, on examining laboratory testing in the era of precision medicine, September 20, 2016
Pubbl/distr/stampa Washington : , : U.S. Government Publishing Office, , 2018
Descrizione fisica 1 online resource (iii, 60 pages)
Collana S. hrg.
Soggetto topico Diagnosis, Laboratory - United States
Personalized medicine - United States
Medical technology - United States
Medical innovations - United States
Diagnosis, Laboratory
Medical innovations
Medical technology
Personalized medicine
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Altri titoli varianti Laboratory testing in the era of precision medicine
Record Nr. UNINA-9910713392303321
Washington : , : U.S. Government Publishing Office, , 2018
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Personalized Medicine in Healthcare Systems [[electronic resource] ] : Legal, Medical and Economic Implications / / edited by Nada Bodiroga-Vukobrat, Daniel Rukavina, Krešimir Pavelić, Gerald G. Sander
Personalized Medicine in Healthcare Systems [[electronic resource] ] : Legal, Medical and Economic Implications / / edited by Nada Bodiroga-Vukobrat, Daniel Rukavina, Krešimir Pavelić, Gerald G. Sander
Edizione [1st ed. 2019.]
Pubbl/distr/stampa Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019
Descrizione fisica 1 online resource (405 pages)
Disciplina 615.7
Collana Europeanization and Globalization
Soggetto topico Personalized medicine
Public health
Health economics
Precision Medicine
Public Health
ISBN 3-030-16465-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Part I -- Introduction -- Options for Realising and Financing Innovation in the German Healthcare System -- Clinical Evaluation of Medical Devices in Europe -- Personalized Medicine: Cutting Edge Developments -- Part II -- Methodological and Technological Aspects Important for Personalised Medicine -- Nanotechnology Approaches for Autologous Stem Cell Manipulation in Personalized Regenerative Medicine -- Patient–Doctor Relationship: Data Protection in the Context of Personalised Medicine -- High-Throughput Analytics in the Function of Personalized Medicine -- Bacteria—Human Interactions: Leads for Personalized Medicine -- Present and Future in Personalized Clinical and Laboratory Approaches to In Vitro Fertilization Procedures. -- Microbiota: Novel Gateway Towards Personalised Medicine -- The Right Not to Know in the Context of Genetic Testing -- Part III -- Social and Humanistic Aspects of Personal Medicine -- Personalized Medicine, Justice and Equality -- Evolution Paths of Business Models in Personalized Medicine -- Socio-Humanistic and Political Context of Personalized Medicine -- Personalized Medicine and Personalized Pricing: Degrees of Price Discrimination -- Personalised Medicine in Health Care Systems and EU Law: The Role of Solidarity?. Personalizing Privacy? Examining the Shifting Boundaries of a Fundamental Right in Preimplantation Genetic Testing of Embryos -- (Bio)ethical Aspects of Personalised Medicine: Revealing an “Inconvenient Truth”? -- Patient-Physician Relationship in Personalized Medicine -- Barriers Towards New Medicine: Personalized and Integrative Medicine Concepts -- The Reverse Payment Settlements in the European Pharmaceutical Market -- Doping in Sports: Legal and Other Aspects -- Personalised Medicine in Public Healthcare Systems -- Part IV -- Clinical Aspects of Personalised Medicine -- Targeted Breast Cancer Therapy -- Personalized Medicine in Ophthalmology: Treatment of Total Limbal Stem Cell Deficiency with Autologous Ex Vivo Cultivated Limbal Epithelial Stem Cell Graft -- Personalized Total Knee Arthroplasty: Better Fit for Better Function -- Comprehensive Approach to Personalized Medicine into Chronic Musculoskeletal Diseases -- Circadian Rhythms and Personalized Melanoma Therapy -- Genetic and Epigenetic Profiling in Personalized Medicine: Advances in Treatment of Acute Myeloid Leukemia -- The Future of Cartilage Repair.
Record Nr. UNINA-9910349375203321
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Personalized medicine in the making : philosophical perspectives from biology to healthcare / / edited by Chiara Beneduce and Marta Bertolaso
Personalized medicine in the making : philosophical perspectives from biology to healthcare / / edited by Chiara Beneduce and Marta Bertolaso
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2022]
Descrizione fisica 1 online resource (333 pages)
Disciplina 610.28
Collana Human Perspectives in Health Sciences and Technology
Soggetto topico Personalized medicine
ISBN 3-030-74804-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910552735203321
Cham, Switzerland : , : Springer, , [2022]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle / / edited by Faik Atroshi
Personalized Medicine, in Relation to Redox State, Diet and Lifestyle / / edited by Faik Atroshi
Pubbl/distr/stampa London : , : IntechOpen, , 2020
Descrizione fisica 1 online resource (xi, 202 pages) : illustrations
Disciplina 615.7
Soggetto topico Personalized medicine
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910688452603321
London : , : IntechOpen, , 2020
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Personalized nutrition as medical therapy for high risk diseases / / edited by Nilanjana Maulik
Personalized nutrition as medical therapy for high risk diseases / / edited by Nilanjana Maulik
Pubbl/distr/stampa Boca Raton, Florida ; ; London, England ; ; New York : , : CRC Press, , [2020]
Descrizione fisica 1 online resource (365 pages)
Disciplina 615.854
Soggetto topico Diet therapy
Personalized medicine
ISBN 1-351-62183-1
1-315-11237-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Half Title -- Title Page -- Copyright Page -- Dedication -- Table of Contents -- Preface -- Acknowledgments -- Editor -- Contributors -- Chapter 1 Introduction -- 1.1 Introduction -- 1.2 What Does Personalization Mean -- 1.3 Where to Go from Here -- 1.4 Medicalization of Food -- 1.5 The Genome-Based Health Concept -- 1.6 Way Forward -- References -- Chapter 2 Personalized Nutrition: The New Era of Nutrition -- 2.1 Introduction -- 2.1.1 Defining Personalized Nutrition -- 2.1.2 Origins of Personalized Nutrition as a Formal Scientific Ideology -- 2.2 Theoretical Basis for Personalized Nutrition -- 2.3 Current Perspectives on Personalized Nutrition -- 2.3.1 Nutrient-Gene Interactions -- 2.3.1.1 Biomarkers -- 2.3.2 Altering Human Behavior -- 2.3.3 Age and Stages of Life -- 2.3.4 Gender -- 2.3.5 Environment: The Exposome -- 2.3.5.1 The Microbiome -- 2.3.6 Personalized Nutritional Strategies for Athletic Performance -- 2.4 Closing Remarks -- Abbreviations -- References -- Chapter 3 Personalized Nutrition in Cardiovascular Disease: From Concept to Realization -- 3.1 Epidemiology -- 3.2 Personalized Nutrition (PN) in CVD -- 3.3 PN1: A Healthy Reference Diet for CVD -- 3.4 Diet and CVD: Lessons from and Limitations of Observational Studies -- 3.5 Saturated Fat (SFA) Intake and CVD -- 3.6 Fat Quality and CVD -- 3.7 Protein Intake and CVD Risk -- 3.8 Carbohydrate Intake and CVD Risk -- 3.8.1 Glycemic Index/Load (GI/GL) -- 3.8.2 Fiber -- 3.8.3 Glucose/Fructose -- 3.9 Dietary Cholesterol and Plant Sterols and Stanols and CVD Risk -- 3.9.1 Dietary Cholesterol -- 3.9.2 Plant Sterols and Stanols -- 3.9.3 Salt Intake and CVD Risk -- 3.10 PN1: Healthy Diet Recommendations for Patients with, or at Risk of, CVD -- 3.11 PN2: Tailoring Dietary Advice to Manage CVD Based on a Person's Phenotype.
3.12 PN3: Tailoring Nutritional Advice to Genetic Composition: From Concept to Realization -- 3.13 Genetics and CVD: Testing the Nature versus Nurture Hypothesis -- 3.14 GWAS and CVD -- 3.15 PN3: Proof of Concept from LIPGENE -- 3.16 PN3: The Challenge of Keeping Up with GWAS -- 3.17 Perspective on the Future of PN for CVD: Is Society Ready to Embrace Change? -- Abbreviations -- References -- Chapter 4 Nutraceuticals for Hypertension Control -- 4.1 Hypertension -- 4.2 Epidemiology -- 4.3 Hypertension Can Be Classified into Two Forms: Primary and Secondary -- 4.3.1 Primary Hypertension -- 4.3.1.1 Genetic Factors -- 4.3.1.2 Environmental Factors -- 4.3.1.3 Childhood Risk for Hypertension -- 4.3.2 Secondary Hypertension -- 4.3.3 Complications of Hypertension -- 4.3.4 Treatment of Hypertension -- 4.4 Minerals and Hypertension -- 4.4.1 Sodium -- 4.4.2 Potassium -- 4.4.3 Magnesium -- 4.4.4 Calcium -- 4.4.5 Zinc -- 4.4.6 Copper -- 4.4.7 Chromium -- 4.4.8 Selenium -- 4.4.9 Manganese -- 4.5 Macronutrients Affecting Hypertension -- 4.5.1 Protein -- 4.5.2 Fat and Fatty Acids -- 4.5.3 Carbohydrates -- 4.5.4 Fibers -- 4.6 Micronutrients and Hypertension -- 4.6.1 Vitamins -- 4.6.2 Coenzyme Q10 (Ubiquinone -- 4.7 Antihypertensive Herbs and Their Mechanism of Action -- 4.7.1 Antioxidant Defense -- 4.7.1.1 Flavonoids -- 4.7.1.2 Vitis vinifera (Grapevine)-Resveratrol -- 4.7.1.3 Lycopersicon esculentum (Tomato)-Lycopene -- 4.7.1.4 Camellia sinensis (Green Tea -- 4.7.2 Diuretics -- 4.7.2.1 Taraxacum officinale (Dandelion -- 4.7.2.2 Petroselinum crispus (Parsley -- 4.7.2.3 Urtica dioica (Stinging Nettle -- 4.7.3 ACE-Inhibitors -- 4.7.3.1 Allium ursinum (Ramsons -- 4.7.3.2 Zingiber officinale (Ginger -- 4.7.3.3 Angelica sinensis (Danggui -- 4.7.4 Vasorelaxant Activity: Direct Vasodilators -- 4.7.4.1 Allium cepa (Onion -- 4.7.4.2 Allium sativum (Garlic.
4.7.4.3 Cinnamomum zeylanicum (Cinnamon -- 4.7.5 Calcium Channel Blocker (CCB -- 4.7.5.1 Piper nigrum (Black Pepper -- 4.8 Interactions of Antihypertensive Herbs -- 4.9 Conclusions -- Acknowledgment -- Abbreviations -- References -- Chapter 5 Roles of Daily Diet and Beta-Adrenergic System in the Treatment of Obesity and Diabetes -- 5.1 Introduction -- 5.2 Role of Nutrition in the Development of Diabetes and Obesity -- 5.2.1 Nutrition in Diabetes -- 5.2.1.1 Micronutrients in Diabetes -- 5.2.1.2 Anthocyanins -- 5.2.1.3 Cocoa Flavanols -- 5.2.1.4 Resveratrol -- 5.2.1.5 Cinnamon -- 5.2.1.6 Milk and Dairy Products -- 5.2.1.7 Probiotics -- 5.2.2 Nutrition in Obesity -- 5.2.2.1 Probiotics -- 5.2.2.2 Quercetin -- 5.2.2.3 Resveratrol -- 5.2.2.4 Curcumin -- 5.2.2.5 Sulforaphane -- 5.3 Role of Nutrition in the Function of the Cardiovascular System -- 5.4 Cardiac Function in Diabetes and Obesity -- 5.4.1 Cardiac Dysfunction in Diabetes -- 5.4.2 Cardiac Function in Obesity -- 5.5 Diet and Beta-Adrenergic System Relation in Heart Function -- 5.6 Effect of ß-ARs System on Heart Function in Diabetes and Obesity -- 5.7 ß3-ARs in Diabetes and Obesity -- 5.8 Regulation of ß3-ARs in Heart from Diabetic and Obese Mammalians -- 5.9 Conclusions -- Acknowledgment -- Abbreviations -- References -- Chapter 6 High Carbohydrate Diet-Induced Metabolic Syndrome in the Overweight Body: Association between Organ Dysfunction and Insulin Resistance -- 6.1 Introduction -- 6.2 Carbohydrate-Rich Nutrition and MetS -- 6.3 MetS and Cardiovascular Dysfunction -- 6.4 Structural Alterations and Molecular Mechanisms of Cardiovascular Dysfunction in MetS -- 6.5 Electrical Alterations in the Hearts of MetS Individuals -- 6.6 Cellular Abnormalities in Ca2+ Homeostasis and Insulin Action in Mammalian MetS -- 6.7 Conclusions and Prevention Approaches -- Acknowledgments -- Abbreviations.
References -- Chapter 7 Caloric Restriction in Obesity and Diabetic Heart Disease -- 7.1 Introduction -- 7.1.1 Cardiovascular Consequences of Diabetes -- 7.2 Metabolic and Molecular Consequences of Diabetes -- 7.2.1 Oxidative Stress -- 7.2.2 Enhanced Inflammatory Response -- 7.2.3 Enhanced Cardiac Fibrosis -- 7.3 Modern Medical Therapies: Implications for the 'Diabetic' Heart -- 7.3.1 Pharmacological Approach, Bariatric Surgery, Intragastric Balloon -- 7.4 Lifestyle Modification -- 7.4.1 Caloric Restriction (CR) -- 7.4.1.1 CR Intracellular Mode of Action -- 7.4.2 Sirtuins -- 7.4.3 PGC-1a -- 7.5 Summary and Future Perspectives -- Abbreviations -- References -- Chapter 8 Personalized Nutrition in Children with Crohn Disease -- 8.1 Introduction -- 8.2 Crohn Disease: An Inflammatory Bowel Disease -- 8.2.1 Crohn Disease and Ulcerative Colitis -- 8.2.2 Pathogenesis of IBD -- 8.2.3 Presentation and Epidemiology of IBD -- 8.2.4 Diagnosis of CD -- 8.3 Relevance of Nutrition and Dietary Factors in the Development of IBD -- 8.4 Nutritional Impacts of CD in Children -- 8.5 Nutritional Therapy for Children with Active CD -- 8.5.1 Induction of Remission with Exclusive Enteral Nutrition -- 8.6 General Aspects of Nutritional Management in Children with IBD -- 8.6.1 Overall Nutritional Care -- 8.6.2 Dietary Management of Functional Symptoms in Children with CD -- 8.7 Application of Current Understanding to the Development of Personalized Nutrition for Children with CD -- 8.7.1 Concepts to Guide Personalized Nutrition -- 8.7.2 Personalization of Nutritional Therapy to Induce Remission -- 8.7.3 Patient and Disease-Specific Factors to Guide Dietary Choices -- 8.7.4 Nutrigenomics, Nutrigenetics and Nutriepigenetics -- 8.8 Conclusions -- Abbreviations -- References -- Chapter 9 Personalized Nutrition in Chronic Kidney Disease: A New Challenge.
9.1 Chronic Kidney Disease: An Epidemic That Reflects Socio-Economic Differences -- 9.1.1 Kidney Diseases Are Not Rare: A Problem of Measure -- 9.1.2 The Main Markers of Kidney Function Are Also Basic Nutritional Markers -- 9.1.3 CKD Assessment: What Is Missed -- 9.1.4 The Epidemiology of Kidney Diseases Follows Wealth Distribution -- 9.2 Nutritional Approach to CKD: Ten Reasons Why One Size Does Not Fit All -- 9.2.1 Kidney Diseases Are Different -- 9.2.2 CKD Phases Are Different -- 9.2.3 Comorbidity Is Different -- 9.2.4 Cultures Are Different -- 9.2.5 Dietary Habits Are Different -- 9.2.6 Availability of Nutritional Support Is Different -- 9.2.7 Nephrologists (and Dietitians) Are Different -- 9.2.8 Life Phases Are Different -- 9.2.9 Patients Are Different -- 9.2.10 Most of the Previous Points May Change -- 9.3 Nutritional Issues in Different Phases of CKD -- 9.3.1 Early CKD Phases: Nephron Sparing -- 9.3.2 Late CKD Phases: Retarding Dialysis Start -- 9.3.3 Dialysis: Preserving Nutritional Status -- 9.3.4 Kidney Transplantation: Preserving Nutritional Status and Slowing CKD Progression -- 9.4 Some Suggestions on Specific Nutritional Issues in Different Diseases -- 9.4.1 Nephrotic Syndrome and the Case of Focal Segmental Glomerulosclerosis -- 9.4.2 Obesity-Related Kidney Disease and Diabetic Nephropathy -- 9.4.3 Autosomal Dominant Polycystic Kidney Disease (ADPKD) -- 9.4.4 Interstitial Disorders and Kidney Stones -- 9.4.5 Kidney Donation -- 9.5 Nutritional Issues in Particular CKD Populations -- 9.5.1 Pregnant Women with CKD -- 9.5.2 Children with CKD -- 9.6 What This Review Did Not Discuss: Suggestions for Further Research -- 9.7 Concluding Remarks -- Abbreviations -- References -- Chapter 10 Personalized Nutrition in Hypercholesterolemia -- 10.1 Personalized Nutrition in Hypercholesterolemia -- 10.2 Cardiovascular Diseases (CVD).
10.3 Coronary Heart Disease (CHD).
Record Nr. UNINA-9910794143903321
Boca Raton, Florida ; ; London, England ; ; New York : , : CRC Press, , [2020]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Personalized nutrition as medical therapy for high risk diseases / / edited by Nilanjana Maulik
Personalized nutrition as medical therapy for high risk diseases / / edited by Nilanjana Maulik
Pubbl/distr/stampa Boca Raton, Florida ; ; London, England ; ; New York : , : CRC Press, , [2020]
Descrizione fisica 1 online resource (365 pages)
Disciplina 615.854
Soggetto topico Diet therapy
Personalized medicine
ISBN 1-351-62183-1
1-315-11237-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Half Title -- Title Page -- Copyright Page -- Dedication -- Table of Contents -- Preface -- Acknowledgments -- Editor -- Contributors -- Chapter 1 Introduction -- 1.1 Introduction -- 1.2 What Does Personalization Mean -- 1.3 Where to Go from Here -- 1.4 Medicalization of Food -- 1.5 The Genome-Based Health Concept -- 1.6 Way Forward -- References -- Chapter 2 Personalized Nutrition: The New Era of Nutrition -- 2.1 Introduction -- 2.1.1 Defining Personalized Nutrition -- 2.1.2 Origins of Personalized Nutrition as a Formal Scientific Ideology -- 2.2 Theoretical Basis for Personalized Nutrition -- 2.3 Current Perspectives on Personalized Nutrition -- 2.3.1 Nutrient-Gene Interactions -- 2.3.1.1 Biomarkers -- 2.3.2 Altering Human Behavior -- 2.3.3 Age and Stages of Life -- 2.3.4 Gender -- 2.3.5 Environment: The Exposome -- 2.3.5.1 The Microbiome -- 2.3.6 Personalized Nutritional Strategies for Athletic Performance -- 2.4 Closing Remarks -- Abbreviations -- References -- Chapter 3 Personalized Nutrition in Cardiovascular Disease: From Concept to Realization -- 3.1 Epidemiology -- 3.2 Personalized Nutrition (PN) in CVD -- 3.3 PN1: A Healthy Reference Diet for CVD -- 3.4 Diet and CVD: Lessons from and Limitations of Observational Studies -- 3.5 Saturated Fat (SFA) Intake and CVD -- 3.6 Fat Quality and CVD -- 3.7 Protein Intake and CVD Risk -- 3.8 Carbohydrate Intake and CVD Risk -- 3.8.1 Glycemic Index/Load (GI/GL) -- 3.8.2 Fiber -- 3.8.3 Glucose/Fructose -- 3.9 Dietary Cholesterol and Plant Sterols and Stanols and CVD Risk -- 3.9.1 Dietary Cholesterol -- 3.9.2 Plant Sterols and Stanols -- 3.9.3 Salt Intake and CVD Risk -- 3.10 PN1: Healthy Diet Recommendations for Patients with, or at Risk of, CVD -- 3.11 PN2: Tailoring Dietary Advice to Manage CVD Based on a Person's Phenotype.
3.12 PN3: Tailoring Nutritional Advice to Genetic Composition: From Concept to Realization -- 3.13 Genetics and CVD: Testing the Nature versus Nurture Hypothesis -- 3.14 GWAS and CVD -- 3.15 PN3: Proof of Concept from LIPGENE -- 3.16 PN3: The Challenge of Keeping Up with GWAS -- 3.17 Perspective on the Future of PN for CVD: Is Society Ready to Embrace Change? -- Abbreviations -- References -- Chapter 4 Nutraceuticals for Hypertension Control -- 4.1 Hypertension -- 4.2 Epidemiology -- 4.3 Hypertension Can Be Classified into Two Forms: Primary and Secondary -- 4.3.1 Primary Hypertension -- 4.3.1.1 Genetic Factors -- 4.3.1.2 Environmental Factors -- 4.3.1.3 Childhood Risk for Hypertension -- 4.3.2 Secondary Hypertension -- 4.3.3 Complications of Hypertension -- 4.3.4 Treatment of Hypertension -- 4.4 Minerals and Hypertension -- 4.4.1 Sodium -- 4.4.2 Potassium -- 4.4.3 Magnesium -- 4.4.4 Calcium -- 4.4.5 Zinc -- 4.4.6 Copper -- 4.4.7 Chromium -- 4.4.8 Selenium -- 4.4.9 Manganese -- 4.5 Macronutrients Affecting Hypertension -- 4.5.1 Protein -- 4.5.2 Fat and Fatty Acids -- 4.5.3 Carbohydrates -- 4.5.4 Fibers -- 4.6 Micronutrients and Hypertension -- 4.6.1 Vitamins -- 4.6.2 Coenzyme Q10 (Ubiquinone -- 4.7 Antihypertensive Herbs and Their Mechanism of Action -- 4.7.1 Antioxidant Defense -- 4.7.1.1 Flavonoids -- 4.7.1.2 Vitis vinifera (Grapevine)-Resveratrol -- 4.7.1.3 Lycopersicon esculentum (Tomato)-Lycopene -- 4.7.1.4 Camellia sinensis (Green Tea -- 4.7.2 Diuretics -- 4.7.2.1 Taraxacum officinale (Dandelion -- 4.7.2.2 Petroselinum crispus (Parsley -- 4.7.2.3 Urtica dioica (Stinging Nettle -- 4.7.3 ACE-Inhibitors -- 4.7.3.1 Allium ursinum (Ramsons -- 4.7.3.2 Zingiber officinale (Ginger -- 4.7.3.3 Angelica sinensis (Danggui -- 4.7.4 Vasorelaxant Activity: Direct Vasodilators -- 4.7.4.1 Allium cepa (Onion -- 4.7.4.2 Allium sativum (Garlic.
4.7.4.3 Cinnamomum zeylanicum (Cinnamon -- 4.7.5 Calcium Channel Blocker (CCB -- 4.7.5.1 Piper nigrum (Black Pepper -- 4.8 Interactions of Antihypertensive Herbs -- 4.9 Conclusions -- Acknowledgment -- Abbreviations -- References -- Chapter 5 Roles of Daily Diet and Beta-Adrenergic System in the Treatment of Obesity and Diabetes -- 5.1 Introduction -- 5.2 Role of Nutrition in the Development of Diabetes and Obesity -- 5.2.1 Nutrition in Diabetes -- 5.2.1.1 Micronutrients in Diabetes -- 5.2.1.2 Anthocyanins -- 5.2.1.3 Cocoa Flavanols -- 5.2.1.4 Resveratrol -- 5.2.1.5 Cinnamon -- 5.2.1.6 Milk and Dairy Products -- 5.2.1.7 Probiotics -- 5.2.2 Nutrition in Obesity -- 5.2.2.1 Probiotics -- 5.2.2.2 Quercetin -- 5.2.2.3 Resveratrol -- 5.2.2.4 Curcumin -- 5.2.2.5 Sulforaphane -- 5.3 Role of Nutrition in the Function of the Cardiovascular System -- 5.4 Cardiac Function in Diabetes and Obesity -- 5.4.1 Cardiac Dysfunction in Diabetes -- 5.4.2 Cardiac Function in Obesity -- 5.5 Diet and Beta-Adrenergic System Relation in Heart Function -- 5.6 Effect of ß-ARs System on Heart Function in Diabetes and Obesity -- 5.7 ß3-ARs in Diabetes and Obesity -- 5.8 Regulation of ß3-ARs in Heart from Diabetic and Obese Mammalians -- 5.9 Conclusions -- Acknowledgment -- Abbreviations -- References -- Chapter 6 High Carbohydrate Diet-Induced Metabolic Syndrome in the Overweight Body: Association between Organ Dysfunction and Insulin Resistance -- 6.1 Introduction -- 6.2 Carbohydrate-Rich Nutrition and MetS -- 6.3 MetS and Cardiovascular Dysfunction -- 6.4 Structural Alterations and Molecular Mechanisms of Cardiovascular Dysfunction in MetS -- 6.5 Electrical Alterations in the Hearts of MetS Individuals -- 6.6 Cellular Abnormalities in Ca2+ Homeostasis and Insulin Action in Mammalian MetS -- 6.7 Conclusions and Prevention Approaches -- Acknowledgments -- Abbreviations.
References -- Chapter 7 Caloric Restriction in Obesity and Diabetic Heart Disease -- 7.1 Introduction -- 7.1.1 Cardiovascular Consequences of Diabetes -- 7.2 Metabolic and Molecular Consequences of Diabetes -- 7.2.1 Oxidative Stress -- 7.2.2 Enhanced Inflammatory Response -- 7.2.3 Enhanced Cardiac Fibrosis -- 7.3 Modern Medical Therapies: Implications for the 'Diabetic' Heart -- 7.3.1 Pharmacological Approach, Bariatric Surgery, Intragastric Balloon -- 7.4 Lifestyle Modification -- 7.4.1 Caloric Restriction (CR) -- 7.4.1.1 CR Intracellular Mode of Action -- 7.4.2 Sirtuins -- 7.4.3 PGC-1a -- 7.5 Summary and Future Perspectives -- Abbreviations -- References -- Chapter 8 Personalized Nutrition in Children with Crohn Disease -- 8.1 Introduction -- 8.2 Crohn Disease: An Inflammatory Bowel Disease -- 8.2.1 Crohn Disease and Ulcerative Colitis -- 8.2.2 Pathogenesis of IBD -- 8.2.3 Presentation and Epidemiology of IBD -- 8.2.4 Diagnosis of CD -- 8.3 Relevance of Nutrition and Dietary Factors in the Development of IBD -- 8.4 Nutritional Impacts of CD in Children -- 8.5 Nutritional Therapy for Children with Active CD -- 8.5.1 Induction of Remission with Exclusive Enteral Nutrition -- 8.6 General Aspects of Nutritional Management in Children with IBD -- 8.6.1 Overall Nutritional Care -- 8.6.2 Dietary Management of Functional Symptoms in Children with CD -- 8.7 Application of Current Understanding to the Development of Personalized Nutrition for Children with CD -- 8.7.1 Concepts to Guide Personalized Nutrition -- 8.7.2 Personalization of Nutritional Therapy to Induce Remission -- 8.7.3 Patient and Disease-Specific Factors to Guide Dietary Choices -- 8.7.4 Nutrigenomics, Nutrigenetics and Nutriepigenetics -- 8.8 Conclusions -- Abbreviations -- References -- Chapter 9 Personalized Nutrition in Chronic Kidney Disease: A New Challenge.
9.1 Chronic Kidney Disease: An Epidemic That Reflects Socio-Economic Differences -- 9.1.1 Kidney Diseases Are Not Rare: A Problem of Measure -- 9.1.2 The Main Markers of Kidney Function Are Also Basic Nutritional Markers -- 9.1.3 CKD Assessment: What Is Missed -- 9.1.4 The Epidemiology of Kidney Diseases Follows Wealth Distribution -- 9.2 Nutritional Approach to CKD: Ten Reasons Why One Size Does Not Fit All -- 9.2.1 Kidney Diseases Are Different -- 9.2.2 CKD Phases Are Different -- 9.2.3 Comorbidity Is Different -- 9.2.4 Cultures Are Different -- 9.2.5 Dietary Habits Are Different -- 9.2.6 Availability of Nutritional Support Is Different -- 9.2.7 Nephrologists (and Dietitians) Are Different -- 9.2.8 Life Phases Are Different -- 9.2.9 Patients Are Different -- 9.2.10 Most of the Previous Points May Change -- 9.3 Nutritional Issues in Different Phases of CKD -- 9.3.1 Early CKD Phases: Nephron Sparing -- 9.3.2 Late CKD Phases: Retarding Dialysis Start -- 9.3.3 Dialysis: Preserving Nutritional Status -- 9.3.4 Kidney Transplantation: Preserving Nutritional Status and Slowing CKD Progression -- 9.4 Some Suggestions on Specific Nutritional Issues in Different Diseases -- 9.4.1 Nephrotic Syndrome and the Case of Focal Segmental Glomerulosclerosis -- 9.4.2 Obesity-Related Kidney Disease and Diabetic Nephropathy -- 9.4.3 Autosomal Dominant Polycystic Kidney Disease (ADPKD) -- 9.4.4 Interstitial Disorders and Kidney Stones -- 9.4.5 Kidney Donation -- 9.5 Nutritional Issues in Particular CKD Populations -- 9.5.1 Pregnant Women with CKD -- 9.5.2 Children with CKD -- 9.6 What This Review Did Not Discuss: Suggestions for Further Research -- 9.7 Concluding Remarks -- Abbreviations -- References -- Chapter 10 Personalized Nutrition in Hypercholesterolemia -- 10.1 Personalized Nutrition in Hypercholesterolemia -- 10.2 Cardiovascular Diseases (CVD).
10.3 Coronary Heart Disease (CHD).
Record Nr. UNINA-9910799933503321
Boca Raton, Florida ; ; London, England ; ; New York : , : CRC Press, , [2020]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Personalized nutrition as medical therapy for high risk diseases / / edited by Nilanjana Maulik
Personalized nutrition as medical therapy for high risk diseases / / edited by Nilanjana Maulik
Pubbl/distr/stampa Boca Raton, Florida ; ; London, England ; ; New York : , : CRC Press, , [2020]
Descrizione fisica 1 online resource (365 pages)
Disciplina 615.854
Soggetto topico Diet therapy
Personalized medicine
ISBN 1-351-62183-1
1-315-11237-X
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Cover -- Half Title -- Title Page -- Copyright Page -- Dedication -- Table of Contents -- Preface -- Acknowledgments -- Editor -- Contributors -- Chapter 1 Introduction -- 1.1 Introduction -- 1.2 What Does Personalization Mean -- 1.3 Where to Go from Here -- 1.4 Medicalization of Food -- 1.5 The Genome-Based Health Concept -- 1.6 Way Forward -- References -- Chapter 2 Personalized Nutrition: The New Era of Nutrition -- 2.1 Introduction -- 2.1.1 Defining Personalized Nutrition -- 2.1.2 Origins of Personalized Nutrition as a Formal Scientific Ideology -- 2.2 Theoretical Basis for Personalized Nutrition -- 2.3 Current Perspectives on Personalized Nutrition -- 2.3.1 Nutrient-Gene Interactions -- 2.3.1.1 Biomarkers -- 2.3.2 Altering Human Behavior -- 2.3.3 Age and Stages of Life -- 2.3.4 Gender -- 2.3.5 Environment: The Exposome -- 2.3.5.1 The Microbiome -- 2.3.6 Personalized Nutritional Strategies for Athletic Performance -- 2.4 Closing Remarks -- Abbreviations -- References -- Chapter 3 Personalized Nutrition in Cardiovascular Disease: From Concept to Realization -- 3.1 Epidemiology -- 3.2 Personalized Nutrition (PN) in CVD -- 3.3 PN1: A Healthy Reference Diet for CVD -- 3.4 Diet and CVD: Lessons from and Limitations of Observational Studies -- 3.5 Saturated Fat (SFA) Intake and CVD -- 3.6 Fat Quality and CVD -- 3.7 Protein Intake and CVD Risk -- 3.8 Carbohydrate Intake and CVD Risk -- 3.8.1 Glycemic Index/Load (GI/GL) -- 3.8.2 Fiber -- 3.8.3 Glucose/Fructose -- 3.9 Dietary Cholesterol and Plant Sterols and Stanols and CVD Risk -- 3.9.1 Dietary Cholesterol -- 3.9.2 Plant Sterols and Stanols -- 3.9.3 Salt Intake and CVD Risk -- 3.10 PN1: Healthy Diet Recommendations for Patients with, or at Risk of, CVD -- 3.11 PN2: Tailoring Dietary Advice to Manage CVD Based on a Person's Phenotype.
3.12 PN3: Tailoring Nutritional Advice to Genetic Composition: From Concept to Realization -- 3.13 Genetics and CVD: Testing the Nature versus Nurture Hypothesis -- 3.14 GWAS and CVD -- 3.15 PN3: Proof of Concept from LIPGENE -- 3.16 PN3: The Challenge of Keeping Up with GWAS -- 3.17 Perspective on the Future of PN for CVD: Is Society Ready to Embrace Change? -- Abbreviations -- References -- Chapter 4 Nutraceuticals for Hypertension Control -- 4.1 Hypertension -- 4.2 Epidemiology -- 4.3 Hypertension Can Be Classified into Two Forms: Primary and Secondary -- 4.3.1 Primary Hypertension -- 4.3.1.1 Genetic Factors -- 4.3.1.2 Environmental Factors -- 4.3.1.3 Childhood Risk for Hypertension -- 4.3.2 Secondary Hypertension -- 4.3.3 Complications of Hypertension -- 4.3.4 Treatment of Hypertension -- 4.4 Minerals and Hypertension -- 4.4.1 Sodium -- 4.4.2 Potassium -- 4.4.3 Magnesium -- 4.4.4 Calcium -- 4.4.5 Zinc -- 4.4.6 Copper -- 4.4.7 Chromium -- 4.4.8 Selenium -- 4.4.9 Manganese -- 4.5 Macronutrients Affecting Hypertension -- 4.5.1 Protein -- 4.5.2 Fat and Fatty Acids -- 4.5.3 Carbohydrates -- 4.5.4 Fibers -- 4.6 Micronutrients and Hypertension -- 4.6.1 Vitamins -- 4.6.2 Coenzyme Q10 (Ubiquinone -- 4.7 Antihypertensive Herbs and Their Mechanism of Action -- 4.7.1 Antioxidant Defense -- 4.7.1.1 Flavonoids -- 4.7.1.2 Vitis vinifera (Grapevine)-Resveratrol -- 4.7.1.3 Lycopersicon esculentum (Tomato)-Lycopene -- 4.7.1.4 Camellia sinensis (Green Tea -- 4.7.2 Diuretics -- 4.7.2.1 Taraxacum officinale (Dandelion -- 4.7.2.2 Petroselinum crispus (Parsley -- 4.7.2.3 Urtica dioica (Stinging Nettle -- 4.7.3 ACE-Inhibitors -- 4.7.3.1 Allium ursinum (Ramsons -- 4.7.3.2 Zingiber officinale (Ginger -- 4.7.3.3 Angelica sinensis (Danggui -- 4.7.4 Vasorelaxant Activity: Direct Vasodilators -- 4.7.4.1 Allium cepa (Onion -- 4.7.4.2 Allium sativum (Garlic.
4.7.4.3 Cinnamomum zeylanicum (Cinnamon -- 4.7.5 Calcium Channel Blocker (CCB -- 4.7.5.1 Piper nigrum (Black Pepper -- 4.8 Interactions of Antihypertensive Herbs -- 4.9 Conclusions -- Acknowledgment -- Abbreviations -- References -- Chapter 5 Roles of Daily Diet and Beta-Adrenergic System in the Treatment of Obesity and Diabetes -- 5.1 Introduction -- 5.2 Role of Nutrition in the Development of Diabetes and Obesity -- 5.2.1 Nutrition in Diabetes -- 5.2.1.1 Micronutrients in Diabetes -- 5.2.1.2 Anthocyanins -- 5.2.1.3 Cocoa Flavanols -- 5.2.1.4 Resveratrol -- 5.2.1.5 Cinnamon -- 5.2.1.6 Milk and Dairy Products -- 5.2.1.7 Probiotics -- 5.2.2 Nutrition in Obesity -- 5.2.2.1 Probiotics -- 5.2.2.2 Quercetin -- 5.2.2.3 Resveratrol -- 5.2.2.4 Curcumin -- 5.2.2.5 Sulforaphane -- 5.3 Role of Nutrition in the Function of the Cardiovascular System -- 5.4 Cardiac Function in Diabetes and Obesity -- 5.4.1 Cardiac Dysfunction in Diabetes -- 5.4.2 Cardiac Function in Obesity -- 5.5 Diet and Beta-Adrenergic System Relation in Heart Function -- 5.6 Effect of ß-ARs System on Heart Function in Diabetes and Obesity -- 5.7 ß3-ARs in Diabetes and Obesity -- 5.8 Regulation of ß3-ARs in Heart from Diabetic and Obese Mammalians -- 5.9 Conclusions -- Acknowledgment -- Abbreviations -- References -- Chapter 6 High Carbohydrate Diet-Induced Metabolic Syndrome in the Overweight Body: Association between Organ Dysfunction and Insulin Resistance -- 6.1 Introduction -- 6.2 Carbohydrate-Rich Nutrition and MetS -- 6.3 MetS and Cardiovascular Dysfunction -- 6.4 Structural Alterations and Molecular Mechanisms of Cardiovascular Dysfunction in MetS -- 6.5 Electrical Alterations in the Hearts of MetS Individuals -- 6.6 Cellular Abnormalities in Ca2+ Homeostasis and Insulin Action in Mammalian MetS -- 6.7 Conclusions and Prevention Approaches -- Acknowledgments -- Abbreviations.
References -- Chapter 7 Caloric Restriction in Obesity and Diabetic Heart Disease -- 7.1 Introduction -- 7.1.1 Cardiovascular Consequences of Diabetes -- 7.2 Metabolic and Molecular Consequences of Diabetes -- 7.2.1 Oxidative Stress -- 7.2.2 Enhanced Inflammatory Response -- 7.2.3 Enhanced Cardiac Fibrosis -- 7.3 Modern Medical Therapies: Implications for the 'Diabetic' Heart -- 7.3.1 Pharmacological Approach, Bariatric Surgery, Intragastric Balloon -- 7.4 Lifestyle Modification -- 7.4.1 Caloric Restriction (CR) -- 7.4.1.1 CR Intracellular Mode of Action -- 7.4.2 Sirtuins -- 7.4.3 PGC-1a -- 7.5 Summary and Future Perspectives -- Abbreviations -- References -- Chapter 8 Personalized Nutrition in Children with Crohn Disease -- 8.1 Introduction -- 8.2 Crohn Disease: An Inflammatory Bowel Disease -- 8.2.1 Crohn Disease and Ulcerative Colitis -- 8.2.2 Pathogenesis of IBD -- 8.2.3 Presentation and Epidemiology of IBD -- 8.2.4 Diagnosis of CD -- 8.3 Relevance of Nutrition and Dietary Factors in the Development of IBD -- 8.4 Nutritional Impacts of CD in Children -- 8.5 Nutritional Therapy for Children with Active CD -- 8.5.1 Induction of Remission with Exclusive Enteral Nutrition -- 8.6 General Aspects of Nutritional Management in Children with IBD -- 8.6.1 Overall Nutritional Care -- 8.6.2 Dietary Management of Functional Symptoms in Children with CD -- 8.7 Application of Current Understanding to the Development of Personalized Nutrition for Children with CD -- 8.7.1 Concepts to Guide Personalized Nutrition -- 8.7.2 Personalization of Nutritional Therapy to Induce Remission -- 8.7.3 Patient and Disease-Specific Factors to Guide Dietary Choices -- 8.7.4 Nutrigenomics, Nutrigenetics and Nutriepigenetics -- 8.8 Conclusions -- Abbreviations -- References -- Chapter 9 Personalized Nutrition in Chronic Kidney Disease: A New Challenge.
9.1 Chronic Kidney Disease: An Epidemic That Reflects Socio-Economic Differences -- 9.1.1 Kidney Diseases Are Not Rare: A Problem of Measure -- 9.1.2 The Main Markers of Kidney Function Are Also Basic Nutritional Markers -- 9.1.3 CKD Assessment: What Is Missed -- 9.1.4 The Epidemiology of Kidney Diseases Follows Wealth Distribution -- 9.2 Nutritional Approach to CKD: Ten Reasons Why One Size Does Not Fit All -- 9.2.1 Kidney Diseases Are Different -- 9.2.2 CKD Phases Are Different -- 9.2.3 Comorbidity Is Different -- 9.2.4 Cultures Are Different -- 9.2.5 Dietary Habits Are Different -- 9.2.6 Availability of Nutritional Support Is Different -- 9.2.7 Nephrologists (and Dietitians) Are Different -- 9.2.8 Life Phases Are Different -- 9.2.9 Patients Are Different -- 9.2.10 Most of the Previous Points May Change -- 9.3 Nutritional Issues in Different Phases of CKD -- 9.3.1 Early CKD Phases: Nephron Sparing -- 9.3.2 Late CKD Phases: Retarding Dialysis Start -- 9.3.3 Dialysis: Preserving Nutritional Status -- 9.3.4 Kidney Transplantation: Preserving Nutritional Status and Slowing CKD Progression -- 9.4 Some Suggestions on Specific Nutritional Issues in Different Diseases -- 9.4.1 Nephrotic Syndrome and the Case of Focal Segmental Glomerulosclerosis -- 9.4.2 Obesity-Related Kidney Disease and Diabetic Nephropathy -- 9.4.3 Autosomal Dominant Polycystic Kidney Disease (ADPKD) -- 9.4.4 Interstitial Disorders and Kidney Stones -- 9.4.5 Kidney Donation -- 9.5 Nutritional Issues in Particular CKD Populations -- 9.5.1 Pregnant Women with CKD -- 9.5.2 Children with CKD -- 9.6 What This Review Did Not Discuss: Suggestions for Further Research -- 9.7 Concluding Remarks -- Abbreviations -- References -- Chapter 10 Personalized Nutrition in Hypercholesterolemia -- 10.1 Personalized Nutrition in Hypercholesterolemia -- 10.2 Cardiovascular Diseases (CVD).
10.3 Coronary Heart Disease (CHD).
Record Nr. UNINA-9910818670603321
Boca Raton, Florida ; ; London, England ; ; New York : , : CRC Press, , [2020]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Precision medicine in cancer treatment
Precision medicine in cancer treatment
Pubbl/distr/stampa [Bethesda, Md.] : , : U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, , 2017
Descrizione fisica 1 online resource : illustrations
Soggetto topico Personalized medicine
Cancer - Gene therapy
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910707056303321
[Bethesda, Md.] : , : U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, , 2017
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
La prévention du risque en médecine : d'une approche populationnelle à une approche personnalisée / / sous la direction de Pierre Corvol
La prévention du risque en médecine : d'une approche populationnelle à une approche personnalisée / / sous la direction de Pierre Corvol
Autore Pierre Corvol (dir.)
Pubbl/distr/stampa Collège de France, 2012
Descrizione fisica 1 online resource (150 pages) : illustrations
Collana Conférences du Collège de France
Soggetto topico Medicine, Preventive
Personalized medicine
Soggetto non controllato prévention médicale
risque statistique
prévention collective
médecine personnalisée
autosoin
ISBN 2-7226-0173-7
2-8218-1900-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione fre
Record Nr. UNINA-9910131936903321
Pierre Corvol (dir.)  
Collège de France, 2012
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Regenerative medicine technology : on-a-chip applications for disease modeling, drug discovery and personalized medicine / / edited by Sean V. Murphy and Anthony Atala
Regenerative medicine technology : on-a-chip applications for disease modeling, drug discovery and personalized medicine / / edited by Sean V. Murphy and Anthony Atala
Pubbl/distr/stampa Boca Raton : , : Taylor & Francis, , [2017]
Descrizione fisica 1 online resource (459 pages) : illustrations (some color)
Disciplina 610.28/4
Collana Gene and cell therapy series
Soggetto topico Artificial organs
Personalized medicine
Regenerative medicine
ISBN 1-315-35415-2
1-315-37134-0
1-4987-1192-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Microfabrication and 3-D bioprinting of organs-on-a-chip -- Three-dimensional cell culture -- Electrochemical sensors for organs-on-a-chip -- Microfluidics -- From big data to predictive analysis from in vitro systems -- Lab-on-a-chip systems for biomedical applications -- From 2D culture to 3D microchip models : trachea, bronchi/bronchiole and lung biomimetic models for disease modeling, drug discovery and personalized medicine -- Liver and liver cancer-on-a-chip -- Heart-on-a-chip -- Skin-on-a-chip -- Tissue engineered kidney models -- Body-on-a-chip -- Integrated multi-organoid dynamics -- Cancer metastasis-on-a-chip -- Breast cancer-on-a-chip -- Disease modeling -- In vivo, in vitro and stem cell technologies to predict human pharmacology and toxicology -- Personalized medicine.
Record Nr. UNINA-9910154882603321
Boca Raton : , : Taylor & Francis, , [2017]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui